Dr. G. Knecht
Veröffentlichungen
Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel FD, Crespi CM, Jacobi V, Staszewski S, Klauke S. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy. Scand J Infect Dis. 2007 Jul 6;:1-4
Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S. Evolution of Resistance Mutations during Low Level Viral Replication in HIV-1 Infected Patients treated with AZT/3TC/ABC (TZV) as First Line Regimen. Antivir Ther. 2007;12(1):25-30.
von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Br J Clin Pharmacol. 2006 Nov;62(5):552-9.
M Bickel, S Zangos, V Jacobi, T Lutz, G Knecht, F Goebel, S Staszewski and S Klauke. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. HIV Medicine 2006: 7: 397–403.
Abstracts
Khaykin P, Staszewski S, Dauer B, Carlebach A, Mueller A, Haberl A, Gute P, Knecht G. Protease inhibitor-based antiretroviral therapy switch to efavirenz-based regimens. 8th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland, 12-16 Nov 2006; Abstract P63.
Knechten H, Lutz T, Knecht G, Stephan C, Carganico A, Gläßel F, Jaeger H, Stoehr A, Tappe A, Wellmann E. The Rainbow Cohort: First results from Germany with the new saquinavir 500 mg formulation. 44th Meeting of the of the Infectious Diseases Society of America (ISDA); Toronto, Canada, Oct 12-15 2006; Abstract 969.
Haberl A., Linde R., Stücker A., Knecht G., Staszewski S. Effective MTCT-prophylaxis with AZT, TDF plus 3TC or FTC. XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada, Abstract CDB0401.
Haberl A, Linde R, Faul-Burbes C, Knecht G, Staszewski S. Effective MTCT-prophylaxis with AZT, TDF plus FTC or 3TC. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PE 14.2/3.
von Hentig N, Carlebach A, Rottmann C, Gute P, Knecht G, Kurowski M, Harder S, Staszewski S. Effect of the co-administration of either Saquinavir (SQV), Lopinavir (LPV) or Fosamprenavir (FosAPV) on Atazanavir (ATV) plasma exposure in boosted double protease inhibitor (PI) therapy regimens. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PS 6/6.
Staszewski S, Khaykin P, Rottmann C, Müller A, Dauer B, Gute P, Knecht G, v.Hentig N, Kurowski M, Stürmer M. Efficacy and safety of a boosted double protease inhibitor (PI) monoclass regimen containing fosamprenavir (FPV), atazanavir (ATV) and ritonavir (RTV) without the addition of other drug classes in antiretroviral therapy (ART)-experienced patients. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PE 7.9/10.
Staszewski S, Dauer B, Locher L, Mösch M, Knecht G, Stürmer M. Intensification of a failing regimen with AZT may cause sustained virologic suppression in the presence of the K65R mutation. 10th European AIDS Conference (EACS); 17-20 Nov 2005; Dublin, Ireland; Abstract PE 7.4/4.
Stürmer M, B. Dauer, M. Moesch, A. Haberl, A. Mueller, L. Locher, G. Knecht, N. Hanke, H.W. Doerr, S. Staszewski. Resistance patterns selected after long-term failure of initial treatment with AZT/3TC/ABC (TZV) reduce treatment options with nucleoside analogues in HIV-infected patients. 10. Deutscher und 16. Österreichischer AIDS-Kongreß; Vienna, Austria 1-4 June 2005; abstract 164.
von Hentig NH, Müller A, Haberl A, Lutz T, Knecht G, Kuowski M, Harder S, Staszewski S. The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor regimen. XV International AIDS Conference; Bangkok 11-16 July 2004; abstract WeOrB1235.
Stürmer M, Dauer B, Mösch M, Haberl A, Müller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S. Resistance patterns selected by initial treatment with AZT/3TC/ABC (TZV) reduce treatment options with nucleoside analogues (NA). 2nd European HIV Drug Resistance Workshop; Rome 11-13 March 11-13, 2004; abstract 4.10.
Staszewski S, Stark T, Knecht, Mösch M, Schlitt C, Dauer B, Warncke W, Walli R. The Quad Study: A Pilot-Study To Assess The Efficacy And Safety Of Trizivir + Rtv-Boosted Saquinavir (TZV+SQV/r) Compared To Combivir + RTV-Boosted Saquinavir (COV+SQV/r) In ART-Naive Patients With High Viral Load (VL) And Low CD4 Count. 24 Week Interim Analysis. 9th European Aids Conference (EACS), 1st EACS Resistance & Pharmacology Workshop; Warsaw, Poland 25 – 29 Oct, 2003; abstract 7.3.
Leder T, Knecht G, M Kurowski, R Hoetelmans, V Miller, S Staszewski. Failure of antiretroviral therapy due to malabsorption disorders and their impact on HIV-resistance. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection 1999; Lisbon, Portugal October 23-27; abstract 1013.
